Studies of determinants of development of inhibitory antibodies to factor VIII in people with hemophilia A indicate a complex process involving multiple factors. The Hemophilia Inhibitor Genetics Study Combined Cohort was formed to extend understanding of the genetic background of risk. The study group contains 833 subjects from three independent cohorts: brother pairs and singletons with and without a history of inhibitors, as well as 104 brother pairs discordant for inhibitor status. Using an Illumina iSelect platform, 13,331 SNPs from 1,081 genes, primarily immune response and immune modifier genes, were typed. Each cohort was analyzed separately with results combined using a meta-analytic technique. After adjustment for potential confounders, 53 SNPs were significant predictors of inhibitor status using the criteria of odds ratios (OR) in the same direction in all cohorts, or allowing for a 20% interval around an OR of 1 in one of the three, and significant in at least two. Of the 53, 13 markers had meta p-values of <0.001. Eight of the 53 were significant predictors among the discordant pairs. Results support the complexity of the immune response, and encourage further research with the goal of understanding the pathways involved.
INTRODUCTION
The treatment of hemophilia has improved significantly over the years, but the development of antibodies that neutralize the effect of the infused factor remains a serious obstacle for patients and care givers. The reasons why only a fraction of patients, 10 to 15% overall, and typically 20 to 30% 1 among those with severe disease develop antibodies remain obscure, but there are several observations indicating that genetic factors are of major importance. The most extensively studied is the type of causative gene mutation 2 . The highest risk has been associated with null-mutations, i.e., mutations considered to result in no protein production, thereby keeping the immune system naive to the deficient factor. In particular, large deletions involving multiple domains confer high risk, and yet, similar to that seen with other high risk mutation types, there are families containing multiple siblings with this mutation who remain inhibitor free 3 .
Independent of the type of causative mutation, the infused factor will be endocytosed in the antigen-presenting cells and proteolytically degraded to smaller peptides that will be presented on the cell surface by the HLA class II molecules to the T-helper cells. This interaction is fundamental for the immune response to occur and without HLA class II molecules with the ability to present the immunogenic peptides to the T-cells, no immune response will take place.
It is therefore not surprising that associations with HLA class II alleles, e.g., DRB*1501 and DQB*0602 have been reported 4 . A higher concordance of inhibitor status than expected between siblings and ethnic variation 4, 5 suggest that other genetic markers may be decisive in the determination of whether or not the immune response occurs. Indeed, genetic markers have been reported, independent of the type of F8 mutation, such as single nucleotide polymorphisms (SNPs) in the genes coding for interleukin1, interleukin 2, interleukin 10, TNFA, TGFβ and
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From [4] CTLA-4 [6] [7] [8] [9] [10] [11] [12] . Since several of the SNPs characterized in immune regulatory molecules coded by the human genome will influence the level of immune modulators, immune system challenges in conjunction with replacement therapy and a genetic predisposition might interact. This is supported by the observations of brother pairs and monozygotic twins with discordant inhibitor status 5 , and the formation of inhibitors in association with significant inflammatory reactions among patients considered to be at low risk 13 .
The goal of the Hemophilia Inhibitor Genetics Study (HIGS) is to contribute to a better understanding of the genetic background of the risk for developing inhibitors. In the current analysis, a large panel of SNPs in and near immune response genes were evaluated in related and unrelated subjects with and without an inhibitor history. In addition to the HIGS cohort, two previously described cohorts were included in this combined analysis, i.e. the Malmö International Brother Study (MIBS) 5 and the Hemophilia Growth and Development Study (HGDS) 14 . The advantages of combining data from these cohorts are twofold. The larger sample size increases statistical power and secondly, we are able to observe the effects of a set of genetic markers on inhibitor development in three studies of differing design. Our method of analysis maximizes the opportunity to identify replication of results among the cohorts, while allowing a more powerful estimation of effect size than might be derived from each individual study. The most significant findings associated with a higher or lower risk in the cohorts are described, as well as the outcome of the genetic markers in 104 brother pairs discordant for inhibitor status.
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METHODS
Population
The HIGS Combined Cohort includes clinical and laboratory data for 833 people with hemophilia A enrolled in one of three studies: HIGS (n=448), the Malmö International Brother Study (MIBS) (n=120), and the Hemophilia Growth and Development Study (HGDS) (n=265). For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From [6] brothers with hemophilia, the oldest brother was chosen first. Then the next oldest brother with the opposite inhibitor status was selected to complete the pair.
Multiple subjects were enrolled in more than one of the three studies. These were identified centrally, and confirmed by site staff. In the case of duplicates, samples and clinical data collected as part of HIGS participation were used.
Clinical Data Collection
Demographic data including date of birth, race/ethnicity, and relationship to other participants were collected. Severe hemophilia was defined as FVIII activity <0.01 IU/mL, moderate as 0.01 -<0.05 IU/mL, and mild as 0.05 -0.40 IU/mL. Inhibitor-related variables including presence or absence of a history of inhibitor, peak and current titer expressed as Bethesda Units (BU) were measured and recorded as previously described 15 . For this analysis, an inhibitor was defined as a current or history of a titer ≥ 1 BU measured at the local laboratory. This cut point allowed for consistent classification of inhibitor status across the three study groups included in the Combined Cohort.
F8 Mutation Typing
Standard methods for the analyses of the F8 gene mutation were used 16 in HIGS and MIBS. In HGDS, the presence or absence of an inversion mutation (inversion/no inversion) was determined for 58% of the HGDS cohort 17 . The remaining HGDS samples were mutation typed by the methods of Oldenburg 16 . [7] Tyr2105Cys, Arg2150His, Arg2163His, Trp2229Cys, Pro2300Leu, and Asn2286Lys), and splice site (at conserved nucleotides at position + or -1 and 2); or low risk: small deletions/insertions (within A-runs), splice site (at position + or -3 or more remote), missense (other regions), or other mutation types based on data from the Haemophilia A Mutation, Structure, Test and Resource Site (HAMSTeRS) database (http://hadb.org.uk), a resource site for study of FVIII genetic variation, and unpublished data from the Bonn center in Germany.
Genotyping
An Illumina iSelect platform was used to genotype 14,626 single nucleotide polymorphisms (SNPs) (Supplementary Appendix 1) from a set of 1,081 genes. The genes -chiefly immune response and immune modifier genes, and cytokines, cytokine receptors, chemokines, chemokine receptors, immune and inflammatory pathway genes, and HLA genes were selected from a literature review of inflammatory and immune genes and pathway public databases. SNPs were selected from a region spanning 5 kb upstream and 1 kp downstream of the target genes using data for Yoruba (YRI) from Nigeria and CEPH Europeans from Utah (CEU) from the International HapMap Project (http://www.hapmap.org). We first selected all known or putative functional coding region (nonsynonymous, insertion, deletions, frameshift) and regulatory SNPs.
Functional status was vetted using information from NCBI, PupaSuite (http://pupasuite.bioinfo.cipf.es) and SNPEffect (http://snpeffect.vib.be/index.php). SNPs that are reported to affect amino acid composition, or occurred in splice sites, exonic splicing enhancer or exonic splicing silencer, or regulatory regions were selected as long as they met minimum Illumina platform restrictions. Using these as the first seeds, we added tagging SNPs
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From [8] (r2>0.8) equally spaced across the targeted gene region. Because of the paucity of exomic SNPs, most of the SNPs were located on introns or non-coding regions.
Genotypes that exhibited significant deviation from Hardy-Weinburg equilibrium (p<0.001) or that exhibited missingness greater than 20% were removed.
Statistical Analysis
Population stratification was adjusted for by using additional ancestry information generated by the Illumina panel to genetically determine race/ethnicity, allowing a more powerful method of classifying ancestry than data obtained by self-reported cultural identity or race. Using the genotypic data produces principal components that account for genetic variability; components were constructed using a subset of unrelated individuals and projected for the remaining individuals using EIGENSOFT
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. The first three principal components were included in the model as continuous covariates.
Combined Cohort. The analysis was performed separately for each cohort because of the varying distributions of related individuals and differences in inclusion criteria for each study.
The HGDS cohort was analyzed with logistic regression, MIBS with Generalized Estimating
Equations (GEE), and HIGS with alternating logistic regression (ALR). The outcome variable was defined as the absence or presence of a current or history of an inhibitor. Covariates included severity of hemophilia for MIBS and HGDS (mild, moderate, severe), year of birth, genetically-identified race, F8 gene mutation risk category in the case of MIBS and HIGS, and an indicator of presence of intron 1 or 22 inversion mutation for HGDS. Several of these For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From [9] covariates have previously been described as having an association with inhibitor development 1,2 . Year of birth was included to adjust for potential differences in environmental or treatment practices that may have affected risk over the period of enrollment of the three cohorts:
1989 to 2010. Each variable was investigated for possible collinearity or correlation with the genotypic scores. Determining which covariates exhibited independence from genotypes ensured that the overlap in variance in the fitted model attributed to each predictor was limited. The primary hypothesis test was performed using the SNP as the main effect of interest, and was modeled in an additive fashion with the number of minor alleles scored for each participant.
Additional models were constructed for subsets of subjects with severe hemophilia A, and for subjects with an inversion mutation.
Once estimates and standard errors were obtained for each cohort model and SNP, they were combined using a meta-analytic technique, summing the estimates weighted by the standard errors. A Chi Square statistic was obtained and tested for the Combined Cohort 19 . Selection of SNPs of interest was performed to identify markers that exhibited effects in the same direction in all three cohorts, or allowing for a 20% interval around an OR of 1 in one of the three to allow for random variation, as well as having a meta p-value of <0.001.
Discordant pairs.
A stratified logistic regression analysis was performed on the discordant pairs, using a family identifier as the stratification variable to create the matched pairs. The year of birth was the only covariate in the analysis. The discordant pair models were performed similarly to the primary models, where the SNP was included as an additive effect, summing the number of the minor alleles.
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RESULTS
Of the 833 people enrolled in the Combined Cohort, 88% had severe, 8% moderate, and 4% mild hemophilia. Fifty-five percent (N=457) had a current, or history of, an inhibitor. The demographic variables are shown, by cohort, in Table 1 .
Of 14,626 markers on the Illumina panel, 13,952 (95%) were successfully genotyped. A total of 13,331 passed the selection criteria and Hardy-Weinburg equilibrium testing.
Combined Cohort. Fifty-three SNPs were found to be significant using the criteria of odds in the same direction, or allowing for a 20% interval around an OR of 1 in one of the three, and significance in at least two cohorts (Supplementary Appendix 2). Selection of those with a meta p-value of <0.001 reduced the list to 13 markers ( Table 2, Table 3 ). Eight of these showed protective effects, compared to five exhibiting potential risk for inhibitor development. The five SNPs associated with an increased risk of inhibitor development are located on the genes CD44, CSF1R, DOCK2, MAPK9, and IQGAP2. Figure 1 is a graphic presentation of the 13 markers
showing results for three groups: 1) the total cohort; 2) those with severe hemophilia, approximately 90% of the total; and 3) those with the inversion mutation, about 50% of the total.
Findings for the severes varied very little from those observed in the total cohort. In most cases, associations were significant for the subset with inversion mutations as well. For this group, For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From [11] however, the confidence intervals were generally wider, reflecting the decrease in sample size.
With a more general correction method, the number of independent tests was determined as described by Gao, Starmer and Martin 21 . Using a 99% threshold from the principal components, the effective number of tests was determined to be 10,261 which results in a suggested threshold of 9.75E-05, and a Sidak correction at 5.0E-06.
Eight participants in the study group were reported to have historical maximum Bethesda titers between 0.6 and <1. A sensitivity analysis supported the results for the 13 SNPs -after removing these subjects from the study group, the direction of the odds ratios for the SNPs was the same, and the maximum difference in the OR magnitude was .07 (SNP rs1882019, 0.52 in the total cohort vs. 0.55 in the sensitivity analysis). The p-values for these SNPs were also very similar, with a maximum difference of 0.0012.
An evaluation of those with high responding (>5 BU, 79.6%) inhibitors yielded similar results to those observed in the total group (data not shown). The group with low response (≤5 BU, 20.4%) inhibitors was too small to examine separately. Given the relative racial/ethnic homogeneity in this population, it was not possible to examine the effects of the SNPs among groups with differing racial ancestry.
The effect of the F8 mutation on inhibitor risk was evaluated in the models for the HIGS and MIBS cohorts. This was not possible in the HGDS, as the size of the group in this cohort that was typed beyond the presence or absence of the inversion mutation (N=71) did not provide sufficient power to reflect the estimate of the effect of F8 mutation. For the HIGS cohort, the [12] effect of having a high risk vs. a low risk F8 mutation was a median odds ratio of 2.05 (interquartile range 2.03, 2.08) independent of the other covariates and the SNP of interest. For the MIBS cohort, the median odds ratios was 1.88 (interquartile range 1.79, 1.91).
There were six non-synonymous markers located on the F8 gene included in the analysis. These were not genotyped with the iSelect panel, but were part of a subset of additional markers typed in the study group. The effect of each marker on the risk of inhibitor was tested. None showed significant associations in our population. 
DISCUSSION
Based on findings to date, it is clear that the pathophysiological immune process is complex and potentially impacted by both genetic and non-genetic factors. Because a primary focus of hemophilia care is identification of subjects at risk -prior to the start of treatment -a more complete characterization of genetic markers associated with inhibitor development is warranted.
The current study is an extensive effort to address this task, and several new candidates that are potentially predictive in the immune response to the deficient factor have been identified. It is the [13] standard that genetic findings be replicated in different cohorts for secure validation, therefore, this study considered demographic, clinical, and laboratory data from three cohorts -each of different study design and including the population-based HGDS -enrolled over a twenty-year period, 1989 through 2010. The cohorts were evaluated separately adjusting for family relationships, year of birth, genetically-determined racial ancestry, hemophilia severity, and type of F8 mutation. The cut-off used for defining inhibitor status (≥ 1 BU) is somewhat above that typically used. While this could have the effect of misclassifying those with very low titer inhibitors as "non-inhibitor", a sensitivity analysis showed that there was little difference in the results when subjects (N=8) with maximum Bethesda titers between 0.6 and <1 BU were excluded from the analysis. Altogether, we identified 53 markers having significance in at least two of the three cohorts at p<0.05 independent of the type of causative mutation and the other covariates. In 13 of the markers, the meta p-value was <0.001. In addition, to maximize the opportunity to challenge our findings by testing them in three cohorts of differing study design, we also tested the SNPs in a subset of brother pairs discordant for inhibitor status. The functions of the most significant markers, and including the eight markers significantly associated with inhibitor risk in the discordant pairs, are briefly summarized. Given minimization of other intervening factors, the subgroup of inhibitor discordant brother pairs are of particular interest.
Although not considering potential non-genetic factors, the observation of consistent significant associations between the markers on these genes strongly suggest that they are important modifiers of the immune response. The majority of markers are known to be involved in various B-and/or T-cell mediated mechanisms and several of the genes code for molecules involved in intracellular signaling pathways, many of which may interact with one another. Our study was designed to test the most likely candidate genes given their physiologic function. Other common For personal use only. on November 16, 2017. by guest www.bloodjournal.org From [14] variants are located near non-immune related genetic regions; however the initial selection focused on the most likely related genes. Different follow-ups may be proposed that capture pathways traditionally not associated with immune related responses. It is also worth noting that the number of unique combinations of marker subsets is nearly infinite in size. In terms of familial rare inherited SNPs, cohorts of brother pairs have limited power to detect this type of association. Our planned follow-up study of family trios (mother, father, affected offspring), however, is designed for this.
Interestingly, in a sizable proportion of cases (n=27; 50.9%), the identified effects of the minor alleles were protective, suggesting the SNPs exert an effect on the gene increasing the capability to down-regulate the immune response to the deficient factor. Therefore, it is easily appreciated that down-regulatory markers may be important and even override the effect of SNPs upregulating the activity of immune regulators and promoting the response. These mechanisms may also modify the risk for inhibitor development associated with immune system challenges, explaining why events such as major surgery and severe trauma may promote inhibitor formation in some, but not all, patients independent of the severity of the disease; and why prophylaxis given at young age may influence inhibitor risk 22 . In this context, it is again important to note that the current analysis has not considered treatment-related factors, i.e., factors that might, in some cases, modulate the inhibitor risk.
The SNPs located in immune regulatory genes previously associated with inhibitor risk in independent cohorts [6] [7] [8] [9] [10] [11] [12] were not consistently associated with risk in this investigation and in the meta analysis combining all three cohorts. Among these previously described candidates, the SNP at location -1082A/G in the promoter region of IL-10 is the most frequently reported finding. In our study, the ORs for this SNP ranged from 0.8 to 1.3 with a meta-p-value of 0.22.
The absence of supporting effects in our cohorts is potentially due to composition differences between HIGS and previously reported populations. In the case of the IL-10 SNP, it is also worth pointing out that the microsatellite in the IL-10 gene associated with inhibitor risk in the MIBS study was not included in this SNP panel. 11 Other possible explanations are the variation and low frequencies of inhibitor-associated minor alleles and genotypes, such as the A allele at -308 in TNFA identified in 2.3 to 17.3% of subjects within the HapMap project, depending on ethnicity, compared to 13.6% in our Combined Cohort. The discrepancy between previously reported populations and our cohort and the low frequencies are also reflected in the homozygous genotypes of the associated SNPs, e.g. <2% for the A-allele at -308 in TNFA. In the case of the T-allele at -318 in CTLA4, the reported frequencies are even less. The low, and change in, frequency potentially affect the power to detect significant associations. Finally, another potential reason is interaction with non-genetic factors not tested in this analysis.
Fully appreciating the importance of these findings for the development of inhibitors will require considerably more research. However, they support the complexity of the immune response, and encourage further research with the goal of understanding the pathways involved, more so than single genetic markers. Whether some pathways will be more important than others is not clear at this stage, but our results suggest that several potential therapeutic targets may be identified in the future for a variety of antibody-mediated diseases, including inhibitor development in hemophilia. The data also support the theory that the formation of antibodies will be influenced by the combination of a genetic predisposition and immune system challenge(s) in a substantial
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From [16] number of patients with the appropriate subset of immuno-competent cells and HLA class II alleles. Furthermore, our findings may be used to define a risk score based on a combination of additive genetic markers. Work toward that goal is currently on-going through an evaluation of the impact of the most significant findings from the candidate gene panel, and including those previously reported. This score will then be validated in yet another independent cohort, to fully appreciate its value in the clinical setting and the possibility for individualized treatment to minimize inhibitor development. Table 3 . Description of the molecules encoded by the genes referenced in Table 2 and Figures 1 and 2. Shown here are the genes on which SNPs most strongly associated with inhibitor development in the Combined Cohort and the discordant pairs are located.
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Gene rs ID Function
MAPK9 rs4147385
The molecule, also known as JNK2, belongs to a group of mitogenactivated protein kinases that has been identified as a significant signaling pathway for the regulation of CD4+ T-cell differentiation. It also seems to influence the Th1/Th2 balance, providing protection against autoimmunity. Gene function has been associated with diabetes type 1 and malignancy 23, 24 .
PDGFRB rs10072056
The beta-type platelet-derived growth factor receptor gene encodes a cell surface protein tyrosine kinase receptor for members of the plateletderived growth factor family. These growth factors are mitogens for cells of mesenchymal origin, which may be of importance for the immune response and the pathophysiology of renal, vascular and fibrotic disorders as well as malignancies 25 .
PCGF2 rs2879097
The Polycomb group (PCG) gene products have been associated with a crucial role for the Th2 dependent immune response and Th2 differentiation by modifying the expression of different cytokines and chemokines and their receptors. Potential significance for various malignant diseases have also been reported 26, 27 .
DOCK2 rs1863993
The gene encodes a protein, which is a member of the DOCK family of guanine nucleotide exchange factors (GEFs) and activates the G-protein Rac in lymphocytes by promoting nucleotide exchange. The molecule is involved in cellular signaling and crucial for B-and T-lymphocyte chemotaxis and adhesion. In addition, the T-cell receptor seems to act through DOCK2. Deficiency causes a severe defect in lymphocyte responses to chemokines, peripheral T-cell distribution and a deficiency in mature CD4 cells. A potential effect of the gene on various disorders such as autoimmune diseases, Alzheimer's disease and malignancies have been described [28] [29] [30] . This glycoprotein is expressed on the majority of immune cells and constitutes a cell-surface marker involved in cell-cell interaction, cell adhesion and migration. Under inflammatory conditions, CD44 on endothelial cells presents hyaluronan on activated T-cells and the pathway(s) by which the protein acts includes lymphocyte activation, recirculation and homing of relevance for various inflammatory diseases and malignant processes 31, 32 .
IQGAP2 rs17652304
IQ-motif-containing GTPase-activating protein, IQGAP2, is a family member of scaffolding proteins involved in a wide range of cellular processes. The protein interacts with components of the cytoskeleton and influences cell-cell interactions, cytokinesis and apoptosis. An association with hepatocellular carcinoma has been described 33, 34 .
CSF1R rs17725712
Colony stimulating factor 1 receptor (CSF1R) encoded by this gene is also known as CD115. It is a cell-surface protein receptor that mediates the growth factor activity of CSF1 regulating differentiation of myeloid progenitors into various cell-lines including monocytes, macrophages, and dendritic cells as well as modulating the innate and adaptive immune systems. The gene product may influence a wide range of pathophysiological processes including inflammation, bone disease and malignancy 35 .
HSP90B1 rs1882019
Heat shock protein 90 kDA B1, also known as gp96, is a chaperone glycoprotein which has been suggested to play an essential role for regulating both the innate and adaptive immunity and modulate SLE, male fertility, as well as malignant processes 36, 37 .
F13A1 rs13206518
A transglutaminase with a well-known cross-linking function in the hemostatic process. Other biological processes, unrelated to this, have also been described and there is an increasing interest in the enzyme in the pathogenesis of inflammatory and autoimmune conditions such as coeliac and inflammatory bowel disease as well as malignancies 38, 39 .
IGSF2 rs2296449
Also previously known as V7 and CD101, a transmembrane glycoprotein expressed on monocytes, granulocytes, dendritic cells and activated T-cells including effector cells and CD4+CD25+Foxp3+ regulatory T-cells. The biological functions of IGSF2 are largely unclear, but data suggest that this transmembrane glycoprotein modulates T-cell activation either directly or indirectly via dendritic cells, that it regulates T-cell proliferation via IL-10 production, and is involved in tolerance induction 40, 41 .
ALOX5AP rs4075131
The molecule encoded by this gene is involved in lipid and glucose metabolism, and will potentially influence the synthesis of inflammatory mediators such as leukotrienes of importance for allergy and inflammatory processes 42 .
MAP2K4 rs3826392
This gene encodes a kinase which is a direct activator of MAP kinases, including MAPK9, in response to various environmental and stress stimulus. It is suggested to mediate survival signals in T-cell development and influence inflammatory and malignant diseases 43, 44 .
PTPRN2
PTPRM PTPRE rs12667537 rs8086815 rs11015985
The transmembrane signaling molecules encoded by these genes are receptor-type tyrosine protein phosphatases. This family of proteins is known to be involved in and regulate a number of cellular processes, such as cell growth and differentiation 45, 46 . MSR1 rs1564819 This gene encodes a plasma membrane receptor, also named For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From [27] CD204, which belongs to a family of scavenger receptors. These receptors are suggested to be significantly involved in the formation of atherosclerotic lesions, but also other functions such as cell growth and interactions and host defense. An association with systemic inflammatory disorders has been suggested 47, 48 .
TNFRSF21 rs10807350
The protein encoded by this gene, also known as death protein 6 (DR6), is a member of the TNF-receptor superfamily and is considered to play an important regulatory role for the generation of adaptive immunity. Deficiencies seem to affect the Th2 response to both T-dependent and independent antigens and the marker has been suggested to be a potential therapeutic target for treating inflammatory and autoimmune diseases as well as malignancies 49, 50 . 
